EXHIBIT 10.1
MYRIAD GENETICS, INC. HAS OMITTED FROM THIS EXHIBIT 10.1 PORTIONS OF THE
AGREEMENT FOR WHICH MYRIAD GENETICS, INC. HAS REQUESTED CONFIDENTIAL TREATMENT
FROM THE SECURITIES AND EXCHANGE COMMISSION. THE PORTIONS OF THE AGREEMENT FOR
WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED ARE MARKED "[ ]" AND SUCH
CONFIDENTIAL PORTIONS HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.
PATENT AND TECHNOLOGY LICENSE AGREEMENT
THIS fourteen (14) page AGREEMENT ("AGREEMENT") is made on this 2nd day
-----------
of December, 1996 by and between the BOARD OF REGENTS ("BOARD") of THE
UNIVERSITY OF TEXAS SYSTEM ("SYSTEM"), an agency of the State of Texas, whose
address is 201 West 7th Street, Austin, Texas 78701, THE UNIVERSITY OF TEXAS
M. D. ANDERSON CANCER CENTER ("MDA"), a component Institution of the SYSTEM and
Myriad Genetics, Inc., a Delaware corporation having a principal place of
business located at 390 Wakara Way, Salt Lake City, Utah 84108 ("LICENSEE").
TABLE OF CONTENTS
RECITALS Page 2
I. EFFECTIVE DATE Page 2
II. DEFINITIONS Page 2
III. LICENSE Page 3
IV. CONSIDERATION, PAYMENTS AND REPORTS Page 4
V. PUBLICATION Page 6
VI. PATENTS AND INVENTIONS Page 7
VII. INFRINGEMENT BY THIRD PARTIES Page 7
VIII. PATENT MARKING Page 8
IX. INDEMNIFICATION Page 8
X. USE OF BOARD AND COMPONENT'S NAME Page 8
XI. CONFIDENTIAL INFORMATION Page 9
XII. ASSIGNMENT Page 9
XIII. TERMS AND TERMINATION Page 9
XIV. WARRANTY: SUPERIOR-RIGHTS Page 11
XV. GENERAL Page 12
SIGNATURES Page 13
EXHIBIT I Page 14
1
RECITALS
A. BOARD owns certain TECHNOLOGY RIGHTS related to LICENSED SUBJECT MATTER,
which were developed at MDA, a component institution of SYSTEM.
B. BOARD desires to have the LICENSED SUBJECT MATTER developed in the LICENSED
FIELD and used for the benefit of LICENSEE, BOARD, SYSTEM, MDA, the
inventor, and the public as outlined in the Intellectual Property Policy
promulgated by the BOARD.
C. LICENSEE wishes to obtain a license from BOARD to practice LICENSED SUBJECT
MATTER.
NOW, THEREFORE, IN CONSIDERATION OF THE MUTUAL COVENANTS AND PREMISES HEREIN
CONTAINED, THE PARTIES HERETO AGREE AS FOLLOWS:
I. EFFECTIVE DATE
1.1 Subject to approval by BOARD, this AGREEMENT shall be effective as of the
date written herein above ("EFFECTIVE DATE").
II. DEFINITIONS
As used in this AGREEMENT, the following terms shall have the meanings
indicated:
2.1 AFFILIATE shall mean any business entity more than 50% owned by LICENSEE,
any business entity which owns more than 50% of LICENSEE, or any business
entity that is more than 50% owned by a business entity that owns more than
50% of LICENSEE.
2.2 LICENSED FIELD shall mean all human and animal diagnostic, preventive and
therapeutic applications within the LICENSED SUBJECT MATTER.
2.3 LICENSED PRODUCTS shall mean any product or service SOLD by LICENSEE
comprising or making use of LICENSED SUBJECT MATTER pursuant to this
AGREEMENT.
2.4 LICENSED SUBJECT MATTER shall mean inventions and discoveries defined
herein as PATENT RIGHTS or as TECHNOLOGY RIGHTS.
2.5 LICENSED TERRITORY shall mean the entire world.
2
2.6 NET SALES shall mean the gross amounts invoiced by LICENSEE from the SALE
of LICENSED PRODUCTS less sales discounts actually granted in amounts
customary in the trade, including but not limited to pharmacy incentive
programs and all other similar sales incentive programs, all governmental
and healthcare rebates, hospital performance incentive program rebates or
charge backs, sales and/or use taxes actually paid, import and/or export
duties actually paid, outbound transportation actually prepaid or allowed,
insurance and postage, amounts actually allowed or credited due to returns
(not exceeding the original billing or invoice amount) and any
uncollectable amounts owed to LICENSEE from SALES of LICENSED PRODUCTS.
2.7 PATENT RIGHTS shall only mean any and all of BOARD'S rights in information
or discoveries claimed in invention disclosures, patents, and/or patent
applications, whether domestic or foreign, and all divisionals,
substitutions, renewals, continuations, continuations-in-part, reissues,
reexaminations or extensions thereof, and any letters patent that issue
thereon as set forth in Exhibit I hereto,subject to the limitations, if
any, set forth therein.
2.8 SALE or SOLD shall mean the transfer or disposition of a LICENSED PRODUCT
for value to a party other than LICENSEE or an AFFILIATE.
2.9 Subject to the limitations, if any, set forth in Exhibit I hereto,
TECHNOLOGY RIGHTS shall mean BOARD'S rights in any technical information,
know-how, process, procedure, composition, device, method, formula,
protocol, technique, software, design, drawing or data created by the
inventors listed in Exhibit I hereto and relating to the subject matter of
PATENT RIGHTS which is not claimed in PATENT RIGHTS but which is necessary
for practicing PATENT RIGHTS.
III. LICENSE
3.1 BOARD, through MDA, hereby grants to LICENSEE a royalty-bearing, exclusive
license under LICENSED SUBJECT MATTER to make, have made, use and/or sell
LICENSED PRODUCTS within LICENSED TERRITORY for use within LICENSED FIELD
and, subject to Paragraph 4.5 herein, shall extend to BOARD's undivided
interest in any LICENSED SUBJECT MATTER developed during the term of this
AGREEMENT and jointly owned by BOARD and LICENSEE. This grant shall be
subject to Paragraph 14.2 and 14.3, hereinbelow , the payment by LICENSEE
to BOARD of all consideration as provided in Paragraph 4.2 of this
AGREEMENT, and shall be further subject to rights retained by BOARD and MDA
to:
(A) Publish the general scientific findings from research related to
LICENSED SUBJECT MATTER, subject to ARTICLE V herein under; AND
3
(B) Subject to the provisions of ARTICLE XI herein below, use any
information contained in LICENSED SUBJECT MATTER for research,
teaching, patient care, and other educationally related purposes.
3.2 LICENSEE shall have the right to extend the license granted herein to any
AFFILIATE provided that such AFFILIATE consents to be bound by all of the
terms and conditions of this AGREEMENT.
3.3 Subject to the Paragraph 3.4 herein below, LICENSEE shall have the right to
grant sublicenses under LICENSED SUBJECT MATTER consistent with the terms
of this AGREEMENT provided that LICENSEE shall be responsible for its
sublicensees relevant to this AGREEMENT, and for diligently collecting all
amounts due LICENSEE from subicensees. In the event a sublicensee pursuant
hereto becomes bankrupt, insolvent or is placed in the hands of a receiver
or trustee, LICENSEE, to the extent allowed under applicable law and in a
timely manner, agrees to use its best reasonable efforts to collect any and
all consideration owed to LICENSEE and to have the sublicense agreement
confirmed or rejected by a court of proper jurisdiction.
3.4 LICENSEE agrees to deliver to MDA a true and correct copy of each
sublicense granted by LICENSEE, and any modification or termination
thereof, within thirty (30) days after execution, modification, or
termination.
3.5 Upon termination of this AGREEMENT, BOARD and MDA agree to accept as
successors to LICENSEE, existing sublicensees in good standing at the date
of termination provided that such sublicensees consent in writing to be
bound by all of the terms and conditions of this AGREEMENT.
IV. CONSIDERATION, PAYMENTS AND REPORTS
4.1 In consideration of rights granted by BOARD to LICENSEE under this
AGREEMENT, LICENSEE agrees to pay MDA the following:
(A) All out-of-pocket expenses incurred by MDA in filing, prosecuting,
enforcing and maintaining PATENT RIGHTS licensed hereunder, for so
long as, and in such countries as, this AGREEMENT remains in effect.
MDA will invoice LICENSEE upon a quarterly basis for expenses incurred
by MDA , and the amounts invoiced will be due and payable by LICENSEE
within thirty (30) days thereafter; AND
(B) A non-refundable prepaid royalty in the amount of [ ] which
shall not reduce the amount of any other payment provided for in this
ARTICLE IV, and which shall be due and payable within thirty (30) days
after execution of this agreement by LICENSEE; AND
4
(C) A running royalty equal to [ ] of LICENSEE's NET SALES of
LICENSED PRODUCTS in national political jurisdictions in the LICENSED
TERRITORY where LICENSED SUBJECT MATTER is covered by one (1) or more
issued patents or pending patent applications. Such royalties shall be
reduced to [ ] of the rate stated above for LICENSEE'S
NET SALES of LICENSED PRODUCTS in national political jurisdictions in
the LICENSED TERRITORY where BOARD and LICENSEE decide not to file
patent applications and therefore LICENSED SUBJECT MATTER is NOT
covered by one (1) or more issued patents or pending patent
applications.
(D) [ ] of all consideration (royalties not included)
other than Research and Development ("R&D") money and direct
equity investment received by LICENSEE from (i) any sublicensee
pursuant to Paragraphs 3.3 and 3.4 herein above and (ii) any assignee
pursuant to Paragraph 12.1 hereinbelow, including but not limited to
up-front payments, marketing, distribution, franchise, option,
license, or documentation fees, bonus and milestone payments, plus[
] of NET SALES of LICENSED PRODUCTS of sublicensee and
LICENSEE (if applicable), all payable within thirty (30) days after
March 31, June 30, September 30, and December 31 of each year during
the term of this AGREEMENT, at which time LICENSEE shall also deliver
to BOARD and MDA a true and accurate report, giving such particulars
of the business conducted by LICENSEE and its sublicensees, if any
exist, during the preceding three (3) calendar months under this
AGREEMENT as necessary for BOARD to account for LICENSEE's payments
hereunder. Such report shall include all pertinent data, including,
but not limited to: (a) the total quantities of LICENSED PRODUCTS
produced; (b) the total SALES, (c) the calculation of royalties
thereon; (d) the total royalties (or minimum royalties) so computed
and due MDA; and (e) all other amounts due MDA herein. Simultaneously
with the delivery of each such report, LICENSEE shall pay to MDA the
amount, if any, due for the period of such report. If no payments are
due, it shall be so reported. Should LICENSEE be obligated to pay
running royalties to third parties to avoid infringing such third
parties' patent rights which otherwise because of infringement would
preclude LICENSEE from practicing LICENSED SUBJECT MATTER, LICENSEE
may reduce the running royalty due MDA by such running royalties to
such third parties, provided, however, the running royalty due MDA
shall in no case be less than one-half the rates stated herein.
5
4.2 As further consideration to BOARD and MDA, LICENSEE at its sole cost and
expense agrees to use its reasonable commercial efforts to:
(a) isolate the [ ] on [ ].
(b) identify mutations of said gene.
4.3 During the Term of this AGREEMENT and for one (1) year thereafter, LICENSEE
shall keep complete and accurate records of its and its sublicensees' SALES
and NET SALES of LICENSED PRODUCTS to enable the royalties payable
hereunder to be determined. LICENSEE shall permit MDA or its
representatives, at MDA's expense, to periodically examine its books,
ledgers, and records once annually during regular business hours and with
reasonable advanced notice for the purpose of and to the extent necessary
to verify any report required under this AGREEMENT. In the event that the
amounts due to MDA are determined to have been underpaid in an amount equal
to or greater than five percent (5%) of the total amount due during the
period of time so examined, LICENSEE shall pay the cost of such
examination, and accrued interest at the highest allowable rate.
4.4 Upon the request of MDA but not more often than once per calendar year,
LICENSEE shall deliver to MDA a written report as to LICENSEE'S (and
sublicensees') efforts and accomplishments during the preceding year in
diligently commercializing LICENSED SUBJECT MATTER in the LICENSED
TERRITORY and LICENSEE'S (and sublicensees') commercialization plans for
the upcoming year.
4.5 All amounts payable hereunder by LICENSEE shall be payable in United States
funds without deductions for taxes, assessments, fees, or charges of any
kind. Checks shall be made payable to The University of Texas M. D.
Anderson Cancer Center and mailed by U.S. Mail to Box 297402, Houston,
Texas 77297 Attention: Manager, Sponsored Programs.
4.6 No payments due or royalty rates under this AGREEMENT shall be reduced as
the result of co-ownership of LICENSED SUBJECT MATTER by BOARD and another
party, including LICENSEE.
V. PUBLICATION
5.1 MDA shall have the right to publish the general scientific findings related
to the LICENSED SUBJECT MATTER, provided such pubication, presentation or
public disclosure is submitted to LICENSEE at least sixty (60) days prior
to submitting it to a journal, editor, or other third party. LICENSEE shall
have sixty (60) days after receipt to review the proposed publication,
presentation or public disclosure.
6
VI. PATENTS AND INVENTIONS
6.1 It is agreed by LICENSEE and MDA that in the event an invention, whether
patentable or not, is made solely by LICENSEE or jointly by LICENSEE and MDA
under the Article 4.2 hereof, LICENSEE shall assign all its right, title and
interest in said invention to MDA, and MDA shall be the sole owner of such
invention. If after consultation with LICENSEE it is agreed by MDA and
LICENSEE that a new patent application should be filed for LICENSED SUBJECT
MATTER, MDA will prepare and file appropriate patent applications, and
LICENSEE will pay the cost of searching, preparing, filing, prosecuting and
maintaining same. If LICENSEE notifies MDA that it does not intend to pay
the cost of an application, or the prosecution or maintenance thereof in a
national political jurisdiction, then MDA may file, prosecute or maintain
such application at its own expense and LICENSEE shall have no rights to
such patent application or patent in that national ploitical jurisdiction.
MDA shall provide LICENSEE with a copy of the application for which LICENSEE
has paid the cost of filing, as well as copies of any documents received or
filed during prosecution thereof.
VII. INFRINGEMENT BY THIRD PARTIES
7.1 LICENSEE shall have the obligation of enforcing at its expense any patent
exclusively licensed hereunder against infringement by third parties and
shall be entitled to retain recovery from such enforcement. LICENSEE shall
pay MDA a royalty on any monetary recovery to the extent that such monetary
recovery by LICENSEE is held to be damages or a reasonable royalty in lieu
thereof. In the event that LICENSEE does not file suit against a
substantial infringer of such patents within six (6) months of knowledge
thereof, then BOARD and MDA shall have the right to enforce any patent
licensed hereunder on behalf of itself and LICENSEE, with MDA retaining all
recoveries from such enforcement.
7.2 In any suit or dispute involving an infringer, the parties shall cooperate
fully, and upon the request and at the expense of the party bringing suit,
the other party shall make available to the party bringing suit at
reasonable times and under appropriate conditions all relevant personnel,
records, papers, information, samples, specimens, and the like which are in
its possession.
7.3 In the event that an action for infringment is brought against LICENSEE,
its AFFILIATES or sublicensees by a third party because of manufacture, use
or sale of LICENSED PRODUCTS, LICENSEE shall defend, at its own cost, any
such third party claim or action. MDA shall cooperate fully in such defense
and furnish to LICENSEE all evidence and assistance.
7
VIII. PATENT MARKING
8.1 LICENSEE agrees that all packaging containing individual LICENSED
PRODUCT(S), and documentation therefor, sold by LICENSEE, SUBSIDIARIES, and
sublicensees of LICENSEE will be marked permanently and legibly with the
number of the applicable patent(s) licensed hereunder in accordance with
each country's patent laws, including Title 35, United States Code.
IX. INDEMNIFICATION
9.1 LICENSEE shall hold harmless and indemnify BOARD, SYSTEM, MDA, its Regents,
officers, employees, students, and agents from and against any claims,
demand, or causes of action whatsoever, costs of suit and reasonable
attorney's fees including without limitation those costs arising on account
of any injury or death of persons or damage to property caused by, or
arising out of, or resulting from, the exercise or practice of the license
granted hereunder by LICENSEE or its officers, employees, agents or
representatives.
X. USE OF BOARD AND COMPONENT'S NAME
10.1 LICENSEE shall not use the name of (or the name of any employee of) MDA,
SYSTEM or BOARD without the advance, express written consent of BOARD
secured through:
The University of Texas
M. D. Anderson Cancer Center
Office of Public Affairs
1515 Holcombe Boulevard
Box 229
Houston, Texas 77030
ATTENTION: Stephen C. Stuyck
8
XI. CONFIDENTIAL INFORMATION
11.1 MDA and LICENSEE each agree that all information contained in documents
marked "confidential" which are forwarded to one by the other shall be
received in strict confidence, used only for the purposes of this
AGREEMENT, and not disclosed by the recipient party (except as required by
law or court order), its agents or employees without the prior written
consent of the other party, unless such information (a) was in the public
domain at the time of disclosure, (b) later became part of the public
domain through no act or omission of the recipient party, its employees,
agents, successors or assigns, (c) was lawfully disclosed to the recipient
party by a third party having the right to disclose it, (d) was already
known by the recipient party at the time of disclosure, (e) was
independently developed or (f) is required to be submitted to a government
agency pursuant to any preexisting obligation.
11.2 MDA's and LICENSEE's obligation of confidence hereunder shall be fulfilled
by using the same degree of care with the other party's confidential
information as it uses to protect its own confidential information. This
obligation shall exist while this AGREEMENT is in force and for a period of
three (3) years thereafter.
XII. ASSIGNMENT
12.1 Except in connection with merger, consolidation or sale of substantially
all of LICENSEE's assets to a third party this AGREEMENT may not be
assigned by LICENSEE without the prior written consent of BOARD.
XIII. TERMS AND TERMINATION
13.1 Subject to Articles 13.2, 13.3 and 13.4 hereinbelow, the term of this
AGREEMENT shall extend from the Effective Date set forth hereinabove to (i)
the full end of the term or terms for which PATENT RIGHTS have not expired,
or (ii)d if only TECHNOLOGY RIGHTS are licensed and no PATENT RIGHTS are
applicable, for a term of fifteen (15) years.
9
13.2 BOARD and MDA shall have the right at any time after one (1) year from
the EFFECTIVE DATE of this AGREEMENT to terminate the license granted
herein in any national political jurisdiction within the LICENSED TERRITORY
if LICENSEE, within ninety (90) days after written notice from MDA of such
intended termination, fails to provide written evidence satisfactory to MDA
that LICENSEE has commercialized or is actively and effectively attempting
to commercialize an invention licensed hereunder within such
jurisdiction(s). Accurate, written evidence provided by LICENSEE to MDA
within said ninety (90) day period that LICENSEE has an effective, ongoing
and active research, development, manufacturing, marketing, or sales
program, as appropriate, directed toward obtaining regulatory approval
and/or production and/or sale of LICENSED PRODUCTS incorporating PATENT
RIGHTS or incorporating TECHNOLOGY RIGHTS within such jurisdiction shall be
deemed satisfactory evidence.
13.3 Subject to any rights herein which survive termination, this AGREEMENT will
earlier terminate in its entirety:
(A) automatically if LICENSEE shall become bankrupt or insolvent and/or if
the business of LICENSEE shall be placed in the hands of a receiver or
trustee, whether by voluntary act of LICENSEE or otherwise; or
(B) (i) upon thirty (30) days written notice by MDA if LICENSEE shall
breach or default on the payment obligations of ARTICLE IV, or use of
name obligations of ARTICLE X; or (ii) upon ninety (90) days written
notice by MDA if LICENSEE shall breach or default on any other
obligation under this AGREEMENT; provided, however, LICENSEE may avoid
such termination if before the end of such thirty (30) or ninety (90)
day period if LICENSEE provides notice and accurate, written evidence
satisfactory to MDA that such breach has been cured and the manner
of such cure; or.
(C) at any time by mutual written agreement between LICENSEE, MDA and
BOARD, or without cause upon one hundred eighty (180) days written
notice by LICENSEE to MDA and, subject to any terms herein which
survive termination.
10
13.4 Upon termination of this AGREEMENT for any cause:
(A) nothing herein shall be construed to release either party of any
obligation matured prior to the effective date of such termination.
(B) LICENSEE covenants and agrees to be bound by the provisions of
ARTICLES IX, X AND XI of this AGREEMENT.
(C) LICENSEE may, after the effective date of such termination, sell all
LICENSED PRODUCTS and parts therefore that it may have on hand at the
date of termination, provided that LICENSEE pays the earned royalty
thereon and any other amounts due pursuant to ARTICLE IV of this
AGREEMENT.
XIV. WARRANTY: SUPERIOR-RIGHTS
14.1 Except for the rights, if any, of the Government of the United States as
set forth hereinbelow, BOARD represents and warrants its belief that it is
the owner of the entire right, title, and interest in and to LICENSED
SUBJECT MATTER, and that it has the sole right to grant licenses
thereunder, and that it has not knowingly granted licenses thereunder to
any other entity that would restrict rights granted hereunder except as
stated herein.
14.2 LICENSEE understands that the LICENSED SUBJECT MATTER may have been
developed under a funding agreement with the Government of the United
States of America and, if so, that the Government may have certain rights
relative thereto. This AGREEMENT is explicitly made subject to the
Government's rights under any such agreement and any applicable law or
regulation, including P.L. 96-517 as amended by P.L. 98-620. To the extent
that there is a conflict between any such agreement, applicable law or
regulation and this AGREEMENT, the terms of such Government agreement,
applicable law or regulation shall prevail.
14.3 LICENSEE understands and agrees that BOARD, by this AGREEMENT, makes no
representation as to the operability or fitness for any use, safety,
efficacy, approvablity by regulatory authorities, time and cost of
development, patentability, and/or breadth of the LICENSED SUBJECT MATTER.
BOARD, by this AGREEMENT, makes no representation as to whether there are
any patents now held, or which will be held, by others or by BOARD in the
LICENSED FIELD, nor does BOARD make any representation that the inventions
contained in PATENT RIGHTS do not infringe any other patents now held or
that will be held by others or by BOARD.
11
14.4 LICENSEE, by execution hereof, acknowledges, covenants and agrees that
LICENSEE has not been induced in anyway by BOARD, SYSTEM, MDA or employees
thereof to enter into this Agreement, and further warrants and represents
that (i) LICENSEE has conducted sufficient due diligence with respect to
all items and issues pertaining to Article XIV herein and all other matters
pertaining to this Agreement; and (ii) LICENSEE has adequate knowledge and
expertise, or has utilized knowledgeable and expert consultants, to
adequately conduct such due diligence, and agrees to accept all risks
inherent herein.
XV. GENERAL
15.1 This AGREEMENT constitutes the entire and only AGREEMENT between the
parties for LICENSED SUBJECT MATTER and all other prior negotiations,
representations, agreements and understandings are superseded hereby. No
agreements altering or supplementing the terms hereof may be made except by
means of a written document signed by the duly authorized representatives
of the parties.
15.2 Any notice required by this AGREEMENT shall be given by prepaid, first
class, certified mail, return receipt requested, and addressed in the case
of BOARD to:
BOARD OF REGENTS
The University of Texas System
201 West Seventh Street
Austin, Texas 78701
ATTENTION: Office of General Counsel
with copy to: The University of Texas
M.D. Anderson Cancer Center
Office of Technology Development
1020 Holcombe Boulevard, Suite 1405
Houston, Texas 77030
ATTENTION: William J. Doty
or in the case of
LICENSEE to: Myriad Genetics, Inc.
390 Wakara WAy
Salk Lake City, Utah 84108
ATTENTION: President
or such other address as may be given from time to time under the terms of
this notice provision.
12
15.3 LICENSEE covenants and agrees to comply with all applicable federal, state
and local laws and regulations in connection with its activities pursuant
to this AGREEMENT.
15.4 This AGREEMENT shall be construed and enforced in accordance with the laws
of the United States of America and of the State of Texas.
15.5 Failure of BOARD to enforce a right under this AGREEMENT shall not act as a
waiver of that right or the ability to later assert that right relative to
the particular situation involved.
15.6 Headings included herein are for convenience only and shall not be used to
construe this AGREEMENT.
15.7 If any provision of this AGREEMENT shall be found by a court to be void,
invalid or unenforceable, the same shall be reformed to comply with
applicable law or stricken if not so conformable, so as not to affect the
validity or enforceability of this AGREEMENT.
IN WITNESS WHEREOF, PARTIES HERETO HAVE CAUSED THEIR DULY AUTHORIZED
REPRESENTATIVES TO EXECUTE THIS AGREEMENT.
THE UNIVERSITY OF TEXAS BOARD OF REGENTS OF THE
M.D. ANDERSON CANCER CENTER UNIVERSITY OF TEXAS SYSTEM
By /s/ Michael J. Best By /s/ Ray Farabee
----------------------------- ------------------------------
Michael J. Best Ray Farabee
Chief Financial Officer Vice Chancellor and
General Counsel
APPROVED AS TO CONTENT: APPROVED AS TO FORM:
By /s/ William J. Doty By /s/ Dudley R. Dobie, Jr.
----------------------------- ------------------------------
William J. Doty Dudley R. Dobie, Jr.
Director, Technology Development Manager, Intellectual Property
MYRIAD GENETICS, INC.
By /s/ Peter D. Meldrum
-----------------------------
Peter D. Meldrum
President and CEO
13
EXHIBIT I
[
]
THE DATA REFERENCED ABOVE IS AGREED TO BE CONFIDENTIAL AND SUBJECT TO THE
CONDITIONS OF ARTICLE XI OF THE AGREEMENT TO WHICH THIS EXHIBIT IS ATTACHED.
14